Literature DB >> 8817103

Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats.

N Yagihashi1, N Nishida, H G Seo, N Taniguchi, S Yagihashi.   

Abstract

Renal haemodynamic changes are suggested to be an early sign of diabetic glomerulopathy. The juxtaglomerular apparatus relevant to the renin angiotensin system, known to be the site of nitric oxide (NO) production, is considered to play a role in the regulation of glomerular blood flow. This study was therefore designed to clarify whether in situ expression of nitric oxide synthase (NOS) is altered in the kidney of diabetic rats. Streptozotocin-induced diabetic rats with 6, 8, 12 and 32 weeks diabetes duration and age-matched normal control rats were used. The expression of a constitutive form of NOS (cNOS, neural type) and NADPH diaphorase activity in the renal cortex were studied immunohistochemically and histochemically. Diabetic rats had lower body weight and heavier kidney mass compared to control rats at each time point examined. Mean glomerular surface area was greater in 6, 8 and 12-week diabetic rats compared to age-matched control rats. cNOS reaction was localized in the macula densa and appeared less intense in diabetic rats compared to age-matched control rats. The mean number of macula densa cells positive for cNOS in each glomerulus and in each glomerular area was significantly lower in diabetic rats compared to control rats at any time examined. In contrast, NADPH diaphorase activity was detected in both juxtaglomerular arterioles and macula densa cells. The staining reaction of NADPH diaphorase in the arterioles remained positive but appeared less intense in macula densa cells in diabetic rats. These results suggest that NO production in macula densa cells may be reduced in diabetic rats, modulating the vasodilatory function of afferent arterioles. Further investigation on the changes in inducible NOS as well as endothelial cNOS are necessary to clarify mechanisms of haemodynamic changes in the diabetic kidney.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8817103     DOI: 10.1007/s001250050512

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

1.  Glomerular size and structure in diabetes mellitus. III. Early enlargement of the capillary surface.

Authors:  J P Kroustrup; H J Gundersen; R Osterby
Journal:  Diabetologia       Date:  1977-05       Impact factor: 10.122

2.  A strong correlation between glomerular filtration rate and filtration surface in diabetic kidney hyperfunction.

Authors:  K Hirose; H Tsuchida; R Osterby; H J Gundersen
Journal:  Lab Invest       Date:  1980-11       Impact factor: 5.662

3.  Abnormally increased glomerular filtration rate in short-term insulin-treated diabetic subjects.

Authors:  J Ditzel; M Schwartz
Journal:  Diabetes       Date:  1967-04       Impact factor: 9.461

4.  Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus.

Authors:  D M Wilson; J A Luetscher
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

5.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Effects of very mild versus overt diabetes on vascular haemodynamics and barrier function in rats.

Authors:  G Pugliese; R G Tilton; A Speedy; K Chang; E Santarelli; M A Province; D Eades; W R Sherman; J R Williamson
Journal:  Diabetologia       Date:  1989-12       Impact factor: 10.122

7.  Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition.

Authors:  M M Pedersen; J S Christiansen; C E Mogensen
Journal:  Diabetes       Date:  1991-05       Impact factor: 9.461

8.  Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction.

Authors:  J A Corbett; R G Tilton; K Chang; K S Hasan; Y Ido; J L Wang; M A Sweetland; J R Lancaster; J R Williamson; M L McDaniel
Journal:  Diabetes       Date:  1992-04       Impact factor: 9.461

Review 9.  Diabetic nephropathy. Metabolic versus hemodynamic considerations.

Authors:  T H Hostetter
Journal:  Diabetes Care       Date:  1992-09       Impact factor: 19.112

10.  Renal function in streptozotocin-diabetic rats.

Authors:  P K Jensen; J S Christiansen; K Steven; H H Parving
Journal:  Diabetologia       Date:  1981-10       Impact factor: 10.122

View more
  5 in total

1.  Ultrastructural localisation of NADPH-d/nNOS expression in the superior cervical ganglion of the hamster.

Authors:  C Y Tseng; J H Lue; H M Chang; C Y Wen; J Y Shieh
Journal:  J Anat       Date:  2000-10       Impact factor: 2.610

2.  Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy.

Authors:  Hanning You; Ting Gao; Timothy K Cooper; Sidney M Morris; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

3.  Polyol pathway and diabetic nephropathy revisited: Early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase.

Authors:  Yasuhiro Hashimoto; Shin-Ichiro Yamagishi; Hiroki Mizukami; Chihiro Yabe-Nishimura; Sun Woo Lim; H Moo Kwon; Soroku Yagihashi
Journal:  J Diabetes Investig       Date:  2011-04-07       Impact factor: 4.232

4.  Renal response to L-arginine in diabetic rats. A possible link between nitric oxide system and aquaporin-2.

Authors:  María C Ortiz; María F Albertoni Borghese; Sabrina E Balonga; Agustina Lavagna; Ana L Filipuzzi; Rosana Elesgaray; María A Costa; Mónica P Majowicz
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

5.  Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism.

Authors:  Hanning You; Ting Gao; Timothy K Cooper; Sidney M Morris; Alaa S Awad
Journal:  Kidney Int       Date:  2013-06-12       Impact factor: 10.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.